Clinical Trial Update: Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

The document notes the completion of a Phase 2 neoadjuvant window trial evaluating afatinib in squamous cell carcinoma of the head and neck.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Status: COMPLETED